23 October – Webinar in connection with Q3 interim report
Alligator hosted a webinar and conference call for investors, analysts on 23 October 2025 where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the interim report. The presentation was followed by a Q&A session.
The call was held in English. Attendees can request a reply at ir@alligatorbioscience.com.
19 August – R&D event
Alligator hosted a virtual R&D Day on Tuesday, 19 August 2025 providing an in-depth update on Alligator’s R&D pipeline, with a primary focus on its lead candidate mitazalimab, ahead of the upcoming TO 13 warrant exercise period (1–15 September 2025).
LATEST NEWS
Alligator Bioscience comments on Henlius receiving regulatory approval in China to initiate Phase 2/3 trials of HLX22 in HER2-positive breast cancer
Lund, Sweden – 9 Dec 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on the announcement by Shanghai Henliu …
Alligator publishes supplement prospectus
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, …
Alligator Bioscience publishes financial calendar for 2026
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2026: Deadline for Alligato …